← Back to calculator
Published Phase 1 human studies
CJC-1295 is an investigational growth-hormone-releasing peptide that is not FDA-approved; this page explains what it is, how the DAC and no-DAC (mod GRF 1-29) forms differ in half-life, and the safety signals to know — while the mg-to-units math lives on the CJC-1295 dosage calculator.
Peptide Calculator X
Reconstitution / draw volume / syringe units / supply-chain
Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.
Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.
Reverse: pick a dose and the units you want it to read, then calculate diluent to add.
CJC-1295: reference record
| Regulatory status | Investigational; not FDA-approved |
|---|---|
| Route | Subcutaneous (CJC-1295 with DAC in cited study) |
| Dosing frequency | Single or study-scheduled |
| Published range | 30–60 mcg/kg |
| Evidence basis | Published Phase 1 human studies |
| Common vial sizes | 5, 10 (DAC / no-DAC) |
Sources
- PubMed - PMID 16352683Basis for the regulatory status, route, frequency and published range in the table above. Source last checked 2026-06-24
What is CJC-1295?
CJC-1295 is an investigational growth-hormone-releasing peptide. It exists in two forms that behave differently: the DAC version, which binds to albumin and persists far longer in circulation, and the no-DAC form often sold as mod GRF 1-29, which clears quickly.
Is CJC-1295 FDA-approved?
No. CJC-1295 is investigational and not FDA-approved. The published human data come from early-phase studies rather than from an approved product label, so there is no approved formulation or indication.
How is CJC-1295 given?
The cited human study used the DAC form subcutaneously, on a single or study-scheduled basis. There is no approved outpatient route or regimen, and the two forms are not interchangeable.
What are the known safety concerns with CJC-1295?
Data are limited. The FDA has noted serious adverse events associated with this substance, including increased heart rate and vasodilatory reactions. Nothing here establishes that any route or amount is safe.
Healthy-adult studies examined 30 and 60 mcg/kg among ascending doses; protocol-controlled
Weight-based conversion supported mathematically, but CJC-1295 with DAC must not be confused with 'no-DAC' products.
Limited data; FDA notes serious adverse events including increased heart rate and vasodilatory reaction.
Supply-chain quality · Finnrick
Avg quality score
5
/10
Purity range
68.75
–
99.95
%
Qty divergence
±
100
%
Vendors · samples
49
·
266
Common vial sizes
5, 10 (DAC / no-DAC)
mg
Test window
Dec 2024 - May 2026
Related calculators & comparisons
COMPARISONS
Browse all peptides →